Oculus Innovative Sciences Announces Fiscal Third Quarter 2013 Financial Results and Conference Call Jan 31, 2013
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Treatment of Skin Ulcers With Microcyn(R) Technology Dec 27, 2012
In Preparation for European Partnership, Oculus Innovative Sciences Expects Expanded Label Claim for European Formulation of Dermacyn(TM) Wound Care Dec 24, 2012
Oculus Innovative Sciences to Host New York City Financial Analysts Presentation on November 28, 2012 Nov 27, 2012
Oculus Innovative Sciences to Create Subsidiary for Company's Anti-Infective Drug Assets Nov 26, 2012
Oculus Innovative Sciences Completes Patient Enrollment in Study of Microcyn(R) Hydrogel in Management of Scars Nov 14, 2012
Oculus Innovative Sciences Announces Publication of Results From Study of Microcyn(R) Technology-Based Antipruritic Hydrogel in Treatment of Atopic Dermatitis Sep 27, 2012
